Table 1 Correlation between TCTN1 expression and clinicopathologic characteristics of 110 GBM patients in the Chinese cohort
From: Expression and prognostic significance of TCTN1 in human glioblastoma
Characteristics | No. patients | TCTN1 expression | P* | |
|---|---|---|---|---|
Low | High | |||
Gender | Â | Â | Â | 0.378 |
 Male | 74(67.3%) | 20(27.0%) | 54(73.0%) |  |
 Female | 36(32.7%) | 13(36.1%) | 23(63.9%) |  |
Age (year) | Â | Â | Â | 0.211 |
 ≥53 | 52(47.3%) | 19(36.5%) | 33(63.5%) |  |
 <53 | 58(52.7%) | 14(24.1%) | 44(75.9%) |  |
Tumor origin | Â | Â | Â | 0.670 |
 Primary | 95(86.4%) | 28(29.5%) | 67(70.5%) |  |
 Secondary | 15(13.6%) | 5(33.3%) | 10(66.7%) |  |
Seizure | Â | Â | Â | 0.349 |
 No | 96(87.3%) | 27(28.1%) | 69(71.9%) |  |
 Yes | 14(12.7%) | 6(42.9%) | 8(57.1%) |  |
IICP | Â | Â | Â | 0.836 |
 No | 59(53.6%) | 17(28.8%) | 42(71.2%) |  |
 Yes | 51(46.4%) | 16(31.4%) | 35(68.6%) |  |
Cystic degeneration | Â | Â | Â | 0.799 |
 No | 82(74.5%) | 25(30.5%) | 57(69.5%) |  |
 Yes | 23(20.9%) | 6(26.1%) | 17(73.9%) |  |
Necrosis | Â | Â | Â | 0.419 |
 No | 90(81.8%) | 25(27.8%) | 65(72.2%) |  |
 Yes | 20(18.2%) | 8(40.0%) | 12(60.0%) |  |
Edge | Â | Â | Â | 0.762 |
 Not clear | 52(47.3%) | 15(28.8%) | 37(71.2%) |  |
 Clear | 17(15.5%) | 6(35.3%) | 11(64.7%) |  |
MTD (cm) | Â | Â | Â | 0.093 |
 < 5 | 46(41.8%) | 18(39.1%) | 28(60.9%) |  |
 ≥5 | 64(58.2%) | 15(23.4%) | 49(76.6%) |  |
Resection | Â | Â | Â | 1.000 |
 ≥98% | 84(76.4%) | 25(29.8%) | 59(70.2%) |  |
 < 98% | 26(23.6%) | 8(30.8%) | 18(69.2%) |  |